Merck Serono Rebif meets primary endpoint in Phase III Reflex 1 study
Reflex study was conducted with the serum-free formulation of Rebif 3, which was first introduced in 2007 and is now available in all EU countries, Australia, Canada and
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.